International Journal of Medicine and Data

Objective To analyze the therapeutic effect of tofacitinib combined with methotrexate in patients with refractory rheumatoid arthritis. Methods 200 patients with refractory rheumatoid arthritis admitted to our hospital were selected as the research objects, and the selection time was from November 2019 to November 2021, and they were randomly divided into the reference group and the treatment group (each group) according to the random number table method. group of 100 cases), the former was treated with leflunomide combined with methotrexate (which was much different from the prescribed plan), and the latter was treated with tofacitinib combined with methotrexate. The health assessment scale (HAQ) of the two groups was compared Score, visual analogue (VAS) score, rheumatoid factor and C-reactive protein levels, ACR disease improvement, DAS28 score, SHARP score. Results Compared with the reference group, the treatment group had lower HAQ score, VAS score, rheumatoid factor, C-reactive protein level, incidence of adverse reactions, swelling and tender joints (P<0.05). The improvement of ACR in the treatment group was significantly better than that in the control group (P<0.05), and the DAS28 score at 3 months and 6 months was significantly lower (P<0.05). The DAS28 score of the treatment group at 3 months and 6 months was significantly lower than that of the reference group, and the difference was statistically significant (P<0.05). There was no significant difference in the DAS28 score at 1 month, and the SHARP score at 1 month, 3 months, and 6 months between the two groups (P>0.05). Conclusion Tofacitinib combined with methotrexate has a good effect in the treatment of refractory rheumatoid arthritis, and it is worth promoting in clinical practice.

Refractory rheumatoid arthritis; Tofacitinib; Methotrexate